A5001717765- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Receptor Mechanisms and Signaling
- Epigenetics and DNA Methylation
- Cancer, Hypoxia, and Metabolism
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Chemical Synthesis and Analysis
- T-cell and B-cell Immunology
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Computational Drug Discovery Methods
- Gene Regulatory Network Analysis
- Animal testing and alternatives
- Immune cells in cancer
- Animal Behavior and Welfare Studies
- Mathematical Biology Tumor Growth
- Statistical Methods in Clinical Trials
- Immunotherapy and Immune Responses
- Single-cell and spatial transcriptomics
AstraZeneca (United Kingdom)
2022-2024
Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these still not clearly defined. The translational relevance differences between is fully understood, impeding appropriate preclinical model selection for target validation, ultimately hindering drug development. Across a panel commonly used murine models, we showed variable responsiveness immunotherapies. We array comparative genomic hybridization, whole-exome...
// Geoffrey S. Williams 1 , Bina Mistry Sandrine Guillard Jane Coates Ulrichsen Alan M. Sandercock Jun Wang 2 Andrea González-Muñoz Julie Parmentier 3 Chelsea Black 4 Jo Soden 5 Jim Freeth Jelena Jovanović Rebecca Leyland Rafia Al-Lamki Andrew J. Leishman Steven Rust Ross Stewart Lutz Jermutus John R. Bradley Vahe Bedian Viia Valge-Archer Ralph Minter Robert W. Wilkinson MedImmune Ltd., Granta Park, Cambridge, CB21 6GH, UK Department of Medicine, University Addenbrooke’s...
Purpose: To generate and characterize a murine GITR ligand fusion protein (mGITRL-FP) designed to maximize valency the potential agonize receptor for cancer immunotherapy.Experimental Design: The EC50 value of mGITRL-FP was compared with an anti-GITR antibody in vitro agonistic cell-based reporter assay. We assessed impact dose, schedule, Fc isotype on antitumor activity T-cell modulation CT26 tumor model. OX40L-FP targeting OX40, B16F10-Luc2 models. Combination antibodies PD-L1, PD-1, or...
In animal experiments, blinding (also known as masking) is a methodological strategy to reduce the risk that scientists, care staff, or other staff involved in research may consciously subconsciously influence outcome. Lack of masking has been shown correlate with an overestimation treatment efficacy and false positive findings. We conducted exploratory interviews across academic commercial setting discuss implementation at four stages experiment: during allocation intervention, conduct...
In anticancer research, tumor growth measured in mouse models is important for assessing treatment efficacy a to progress human clinical trials. Statistical analysis of time-to-event volume data complex because heterogeneity response and welfare-related loss. Traditional statistical methods testing the mean difference between groups are not robust they assume common responses across population. Heterogeneity also seen clinic, consequently, assessment considers diversity through...
Abstract Infiltrating host immune cells can have a significant impact on the growth and outcome of many tumor types. Several leukocyte populations been implicated in establishing an suppressive microenvironment (e.g. myeloid derived suppressor [MDSCs) regulatory T [Treg cells]) thus making it harder for anti-tumor effector to function CD8 cytotoxic cells). Immune-Mediated Therapy (IMT) is emerging as key strategy treatment cancer through by enhancing patient's response. In order maximise...
Abstract Regulatory T cells (Treg cells) are observed within multiple tumor types and contribute to immune evasion. Effective specific targeting of Treg by antibodies is hampered the lack a unique surface marker. With aim identifying such marker, human were isolated from peripheral blood, expanded in vitro used as source antigen phage display selections with diverse library designed ankyrin repeat proteins (DARPins). The resulting DARPins screened for binding cell-types, approximately thirty...
<p>Supplementary figures S1-4</p>
<p>Additional materials and methods supplementary figure legends with tracked changes</p>
<p>Additional materials and methods supplementary figure legends.</p>
<p>Additional materials and methods supplementary figure legends.</p>
<p>Additional materials and methods supplementary figure legends with tracked changes</p>
<p>Supplementary figures S1-4</p>
<div>Abstract<p><b>Purpose:</b> To generate and characterize a murine GITR ligand fusion protein (mGITRL-FP) designed to maximize valency the potential agonize receptor for cancer immunotherapy.</p><p><b>Experimental Design:</b> The EC<sub>50</sub> value of mGITRL-FP was compared with an anti-GITR antibody in <i>in vitro</i> agonistic cell–based reporter assay. We assessed impact dose, schedule, Fc isotype on antitumor...
<div>Abstract<p><b>Purpose:</b> To generate and characterize a murine GITR ligand fusion protein (mGITRL-FP) designed to maximize valency the potential agonize receptor for cancer immunotherapy.</p><p><b>Experimental Design:</b> The EC<sub>50</sub> value of mGITRL-FP was compared with an anti-GITR antibody in <i>in vitro</i> agonistic cell–based reporter assay. We assessed impact dose, schedule, Fc isotype on antitumor...
<div>Abstract<p>Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these still not clearly defined. The translational relevance differences between is fully understood, impeding appropriate preclinical model selection for target validation, ultimately hindering drug development. Across a panel commonly used murine models, we showed variable responsiveness immunotherapies. We array comparative genomic...
<p>Supplementary dataset containing raw data from targeted sequencing, whole exome array CGH and transcriptomic analysis</p>
<p>Supplementary dataset containing raw data from targeted sequencing, whole exome array CGH and transcriptomic analysis</p>
<div>Abstract<p>Murine syngeneic tumor models are critical to novel immuno-based therapy development, but the molecular and immunologic features of these still not clearly defined. The translational relevance differences between is fully understood, impeding appropriate preclinical model selection for target validation, ultimately hindering drug development. Across a panel commonly used murine models, we showed variable responsiveness immunotherapies. We array comparative genomic...